Silence Therapeutics (SLN) Receivables - Net (2019 - 2025)

Silence Therapeutics (SLN) posted Receivables - Net of $28000.0 for Q3 2025, down 67.06% sequentially from $85000.0 in Q2 2025.

Silence Therapeutics (SLN) Receivables - Net (2019 - 2025) Analysis & Trends

Silence Therapeutics has reported Receivables - Net for 7 years, with the latest figure at $28000.0 in Q3 2025.

Quarterly Receivables - Net changed N/A year-over-year to $28000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28000.0 (changed N/A YoY) and the FY2024 annual result came in at $972000.0, up 235.17% from the prior year.
Receivables - Net declined to $28000.0 in Q3 2025 per SLN's latest filing, from $85000.0 in the prior quarter.
Over five years, Receivables - Net peaked at $1.1 million in Q4 2022 and troughed at $28000.0 in Q3 2025.
A 5-year average of $418343.4 and a median of $282982.6 in 2023 frame the typical range for Receivables - Net.
The sharpest annual moves came in 2021 and 2024: Receivables - Net plunged 98.85% in 2021, then soared 243.48% in 2024.
Over 5 years, Receivables - Net stood at $446191.5 in 2021, then jumped by 140.53% to $1.1 million in 2022, then tumbled by 73.63% to $282982.6 in 2023, then jumped by 243.48% to $972000.0 in 2024, then tumbled by 97.12% to $28000.0 in 2025.
According to Business Quant data, Receivables - Net over the past three periods registered $28000.0, $85000.0, and $41000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Silence Therapeutics	648.22 Mn	576.12 Mn	-

Download Data